CIK 0002131524 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Braveheart Bio, Inc.
Sign in to watch- Ticker
- BRVE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 992981994
- Phone
- (415) 707-6312
- Business address
- ONE LETTERMAN DR., BLDG. A, STE. A4-300, SAN FRANCISCO, CA, 94129
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-07 | AH Bio Fund IV, L.P. 10% owner | Conversion | +9,132,420 | 9,132,420 | ||
| 2026-08-07 | AH Bio Fund IV, L.P. 10% owner | Purchase | +1,100,000 | $18.00 | $19.8M | 10,232,420 |
| 2026-08-07 | AH Bio Fund IV, L.P. 10% owner | Conversion · Series A Preferred Stock | −40,000,000 | 0 | ||
| 2026-08-07 | Chimovits Erez Director | Conversion | +9,132,420 | 10,235,159 | ||
| 2026-08-07 | Chimovits Erez Director | Purchase | +1,666,667 | $18.00 | $30.0M | 11,901,826 |
| 2026-08-07 | Chimovits Erez Director | Purchase | +273,333 | $18.00 | $4.9M | 273,333 |
| 2026-08-07 | Chimovits Erez Director | Conversion · Series A Preferred Stock | −40,000,000 | 0 | ||
| 2026-08-07 | ORBIMED ADVISORS LLC Director | Conversion | +9,132,420 | 10,235,159 | ||
| 2026-08-07 | ORBIMED ADVISORS LLC Director | Purchase | +1,666,667 | $18.00 | $30.0M | 11,901,826 |
| 2026-08-07 | ORBIMED ADVISORS LLC Director | Purchase | +273,333 | $18.00 | $4.9M | 273,333 |
| 2026-08-07 | ORBIMED ADVISORS LLC Director | Conversion · Series A Preferred Stock | −40,000,000 | 0 | ||
| 2026-08-07 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | Conversion | +7,420,091 | 7,420,091 | ||
| 2026-08-07 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | Conversion · Non-voting Series A preferred stock | −32,500,000 | 0 | ||
| 2026-08-07 | Rickey James Paul Chief Financial Officer | Purchase | +27,777 | $18.00 | $500K | 520,927 |
| 2026-08-07 | Viehbacher Christopher Director | Purchase | +83,333 | $18.00 | $1.5M | 609,519 |
| 2026-08-07 | Malek David I Director | Purchase | +4,166 | $18.00 | $75K | 533,845 |
| 2026-08-07 | Anderson Michele A. Chief Development Officer | Purchase | +1,111 | $18.00 | $20K | 332,161 |
| 2026-08-07 | Murdoch Travis CEO and President | Purchase | +83,333 | $18.00 | $1.5M | 2,940,670 |
| 2026-08-07 | Lubner David Charles Director | Purchase | +55,555 | $18.00 | $1000K | 55,555 |
| 2026-08-07 | Forbion Growth Opportunities Fund III Cooperatief U.A. 10% owner | Conversion | +9,132,420 | 9,720,546 |
Page 1 of 2 · 34 trades